Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
PRTA(NASDAQ:PRTA) DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025 at 10:55 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed through the investor relati
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
PRTADUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
Kontakt.io Launches Temperature Monitoring Solution for Critical Healthcare Supplies
PRTACloud-based solution monitors temperature and humidity of refrigerators and regulated rooms with real-time alerts to ensure the safety and effectiveness of medications and biologicals NEW YORK, June 17, 2025 /PRNewswire/ -- Kontakt.io, the industry leader in AI-powered RTLS for care...
B of A Securities Downgrades Prothena Corp to Underperform, Lowers Price Target to $4
PRTAOppenheimer Downgrades Prothena Corp to Perform
PRTAPiper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $81
PRTAJMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $29
PRTAExpert Outlook: Prothena Corp Through The Eyes Of 5 Analysts
PRTAChardan Capital Maintains Buy on Prothena Corp, Lowers Price Target to $18
PRTAWhy Is Prothena Stock Trading Lower On Tuesday?
PRTAProthena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and new focus expected.
HC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $14
PRTATrading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times
PRTAProthena Reveals Phase 3 AFFIRM-AL Clinical Trial for Birtamimab In Patients With AL Amyloidosis Did Not Meet Primary Endpoint
PRTATrading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending
PRTAHC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $30
PRTAJMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $78
PRTABeyond The Numbers: 7 Analysts Discuss Prothena Corp Stock
PRTATop 3 Health Care Stocks That Are Preparing To Pump This Quarter
PRTAChardan Capital Maintains Buy on Prothena Corp, Maintains $40 Price Target
PRTAProthena Corp Q1 EPS $(1.12) Misses $(0.97) Estimate, Sales $2.83M Miss $8.05M Estimate
PRTAA Look Ahead: Prothena Corp's Earnings Forecast
PRTAPiper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $110
PRTAProthena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
PRTAHC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target
PRTARBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $20
PRTACantor Fitzgerald Reiterates Overweight on Prothena Corpto Overweight
PRTACitizens Capital Markets Reiterates Market Outperform on Prothena Corp, Maintains $80 Price Target
PRTAHC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target
PRTAChardan Capital Maintains Buy on Prothena Corp, Maintains $40 Price Target
PRTAProthena Estimates FY25 Net Loss Of $(197)M - $(205)M
PRTAProthena Corp Q4 2024 GAAP EPS $(1.08) Misses $(1.04) Estimate, Sales $2.12M Miss $7.53M Estimate
PRTADemystifying Prothena Corp: Insights From 6 Analyst Reviews
PRTAHC Wainwright & Co. Reiterates Buy on Prothena Corp, Lowers Price Target to $48
PRTAChardan Capital Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $40
PRTAB of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22
PRTARoche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
PRTAProthena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease
PRTAA Preview Of Prothena Corp's Earnings
PRTAProthena Corp (NASDAQ:PRTA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Prothena Corp will report an earnings per share (EPS) of $-0.68.
Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock
PRTARBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the space could drive appreciation.
RBC Capital Maintains Outperform on Prothena Corp, Lowers Price Target to $45
PRTA